These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8163700)

  • 1. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin.
    O'Kane MJ; Wisdom GB; Desai ZR; Archbold GP
    J Clin Pathol; 1994 Mar; 47(3):266-8. PubMed ID: 8163700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gamma globulin inhibition of fibrin clot formation.
    Davey FR; Gordon GB; Boral LI; Gottlieb AJ
    Ann Clin Lab Sci; 1976; 6(1):72-7. PubMed ID: 1247286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired dysfibrinogenemia secondary to multiple myeloma.
    Kotlín R; Sobotková A; Riedel T; Salaj P; Suttnar J; Reicheltová Z; Májek P; Khaznadar T; Dyr JE
    Acta Haematol; 2008; 120(2):75-81. PubMed ID: 18841003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An acquired cryoglobulinemia which inhibits fibrin polymerization in a patient with IgG kappa myeloma.
    Panzer S; Thaler E
    Haemostasis; 1993; 23(1):69-76. PubMed ID: 8477911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of a fibrin formation abnormality in a case of multiple myeloma.
    Soria J; Soria C; Samama M; Fine JM; Bousser J
    Scand J Haematol; 1975 Oct; 15(3):207-18. PubMed ID: 812173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma].
    Lopaciuk S; Snigurowicz J; Rostkowska J; Pniejnia-Olszyński W; Powiertowska-Rezmer M
    Acta Haematol Pol; 1978; 9(3):157-64. PubMed ID: 102100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma.
    Lackner H; Hunt V; Zucker MB; Pearson J
    Br J Haematol; 1970 Jun; 18(6):625-36. PubMed ID: 5428623
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma.
    Carr ME; Zekert SL
    Am J Physiol; 1994 Mar; 266(3 Pt 2):H1195-201. PubMed ID: 8160823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-like anticoagulant associated with plasma cell myeloma.
    Chapman GS; George CB; Danley DL
    Am J Clin Pathol; 1985 Jun; 83(6):764-6. PubMed ID: 3923825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increased thrombin time in a patient with multiple myeloma].
    Bohler A; Redondo M; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding diathesis in multiple myeloma.
    Saif MW; Allegra CJ; Greenberg B
    J Hematother Stem Cell Res; 2001 Oct; 10(5):657-60. PubMed ID: 11672511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous antithrombin in a patient with benign paraprotein.
    Gabriel DA; Carr ME; Cook L; Roberts HR
    Am J Hematol; 1987 May; 25(1):85-93. PubMed ID: 3578266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired dysfibrinogenemia secondary to mithramycin toxicity.
    Ashby MA; Lazarchick J
    Am J Med Sci; 1986 Jul; 292(1):53-5. PubMed ID: 2940861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.
    DiMinno G; Coraggio F; Cerbone AM; Capitanio AM; Manzo C; Spina M; Scarpato P; Dattoli GM; Mattioli PL; Mancini M
    J Clin Invest; 1986 Jan; 77(1):157-64. PubMed ID: 2935559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis.
    Shigekiyo T; Kosaka M; Shintani Y; Azuma H; Iishi Y; Saito S
    Acta Haematol; 1989; 81(3):160-5. PubMed ID: 2496565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
    Colwell NS; Tollefsen DM; Blinder MA
    Br J Haematol; 1997 Apr; 97(1):219-26. PubMed ID: 9136969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diverse hemostatic abnormalities in a patient with biclonal multiple myeloma].
    Komiya I; Ito T; Ogata K; Yamada T; Dan KZ; Kuriya S; Nomura T
    Rinsho Ketsueki; 1990 Jan; 31(1):62-5. PubMed ID: 2107347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired fibrin formation in a patient with multiple myeloma presenting the "gelation" phenomenon.
    Ideguchi H; Suehiro T; Ohike M; Ohishi H; Katsuno M; Nishimura J; Ibayashi H
    Nihon Ketsueki Gakkai Zasshi; 1988 Feb; 51(1):109-17. PubMed ID: 3389056
    [No Abstract]   [Full Text] [Related]  

  • 20. ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function.
    Liu CZ; Shih MH; Tsai PJ
    Thromb Haemost; 2005 Aug; 94(2):286-94. PubMed ID: 16113817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.